inflammatory bowel disease
Adaptive Biotechnologies Halts T-Detect Commercialization, Reports 13 Percent Q2 Revenue Growth
Premium
The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.
Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus.
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.
The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.
Adaptive Biotechnologies to Focus on Immune Medicine, Minimal Residual Disease Testing Businesses
Premium
The Seattle-based company said this week that its immune medicine and minimal residual disease testing business arms will drive the firm's future growth.